LBA31 Primary results from IMagyn050/GOG 3015/ENGOT-OV39, a double-blind placebo (pbo)-controlled randomised phase III trial of bevacizumab (bev)-containing therapy +/- atezolizumab (atezo) for newly diagnosed stage III/IV ovarian cancer (OC)

K.N. Moore, M. Bookman, J. Sehouli,A. Miller, C. Anderson,G. Scambia, T. Myers, C. Taskiran, K. Robison,J. Maenpaa, L.J. Willmott,N. Colombo, J. Thomes-Pepin, M.A. Gold,C. Aghajanian, F. Wu, L. Molinero, V. Khor,Y.G. Lin,S. Pignata

Annals of Oncology(2020)

引用 41|浏览44
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要